Oncology

Latest News

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

AJMC Q&A with Coral Omene, MD, PhD | Background image credit: ipopba - stock.adobe.com

Addressing Cancer Care Challenges for Patients, and Ensuring Equity: Coral Omene, MD, PhD

By Laura Joszt, MA
Coral Omene, MD, PhD

June 22nd 2025

Patients with SCLC in the tarlatamab group had significantly longer overall survival, with a median of 13.6 months vs 8.3 months in the chemotherapy group. | Image credit: mi_viri - stock.adobe.com

Tarlatamab Improves SCLC Outcomes After Platinum Chemotherapy

By Jared Kaltwasser

June 19th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 5th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 5th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

September 27th 2016

SBRT Improves Outcomes in Older NSCLC Patients With Stage I Disease

Surabhi Dangi-Garimella, PhD

Use of stereotactic body radiation therapy improved survival in elderly patients diagnosed with early-stage non-small cell lung cancer by about 20% over a decade.

September 27th 2016

The Big "C" — Is Cancer Curable?

Advancement in basic science and medical technology has made cancer a curable disease for many patients. Approximately 40% of Americans will be diagnosed with cancer in their lifetime, but as of 2014, 1 in 22 Americans is a cancer survivor, which equals 14.5 million cancer survivors in the US, explained Joseph C. Alvarnas, MD, director of value-based analytics for the City of Hope.

September 27th 2016

The Patient Lens on Precision Medicine

Jack Whelan, an e-patient advocate and patient with a rare blood disease, spoke at The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Care Meeting. In his presentation, Whelan explained that patient centricity and education is important for all parties in the healthcare industry to better take hold of.

September 27th 2016

How Do Patients Define Value in Cancer Care?

In the United States healthcare system, discussions of value are almost always associated with the equation of quality over cost. However, patients don’t necessarily think that way, explained Yousuf Zafar, MD, MHS, associate professor of medicine and public policy at the Duke Cancer Institute.

September 27th 2016

Oncology and the President's Precision Medicine Initiative

While President Barack Obama outlined a series of budget plans for oncology care in the fall of 2015, which was designed to allocate an estimated $130 million to sequence 1 million volunteers, $70 million to identify “genome drivers” and $10 million to the FDA to build databases, Michael A. Kolodziej, MD, FACP, national medical director of Oncology Solutions at Aetna, believes there to be different areas of oncology care that need more attention and resources. Kolodziej presented at The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Meeting.

September 27th 2016

Updates in Big Data for Oncology: What Are We Learning?

There are a number of issues concerning big data in the oncology world, the most prominent of which concerns the number of patients participating in clinical trials, Robert J. Green, MD, MSCE, vice president of clinical strategy at Flatiron Health, explained during his presentation at The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Meeting. He added that only 4% of adult cancer patients participate in a clinical trial.

September 27th 2016

Outcomes from Mandatory Genetic Testing and Counseling Programs

Family history is at the core of precision medicine, Joy Larsen Haidle, MS, CGC, 2015 president of the National Society of Genetic Counselors, said during her presentation at The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Care Meeting. During her presentation, Haidle explained that while hereditary cancer was traditionally viewed as occurring between 5% and 10% of the cancer population, recent data suggest that number may be a lot closer to 25% today.

September 27th 2016

The Impacts of FDA Regulations on Diagnostics in Oncology

Scott Gottlieb, MD, resident fellow at the American Enterprise Institute; Michael A. Kolodziej, MD, national medical director of oncology strategy at Aetna; Bruce Quinn, MD, PhD, MBA, senior director at FaegreBD Consulting; and Joy Larsen Haidle, MS, CGC, 2015 president of the National Society of Genetic Counselors, discussed the impacts of FDA regulation on diagnostics in oncology during The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Care Meeting. The panel discussion was moderated by Dennis P. Scanlon, professor of health policy and administrator and director of the Center for Health Care and Policy Research at The Pennsylvania State University.

September 27th 2016

Reimbursement Challenges for Oncology Innovations: Who Pays?

Competition as a means of tackling the escalating issue of drug prices is not working, said Peter B. Bach, MD, MAPP, physician at Memorial Sloan Kettering Cancer Center, in a panel discussion at The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Care Meeting. He explained that implementing a system in which the attributes of the drug determine its price is a more reasonable, value-based approach.

September 27th 2016

Using Our Collective Wisdom to Thrive in a Post-SGR World

One of the reasons Julie M. Vose, MD, MBA, FASCO, 2015-2016 president of the American Society of Clinical Oncology, became involved with medicine in the first place was the ability to help patients. However, she said that the administrative burden physicians take on in today’s health system can often take away from that experience.

September 27th 2016

Navigating the Conflict of Personalized Medicine vs Population Management

Population health is a method that looks at the total costs of care, focuses on the prevalent chronic diseases, and, additionally, examines the various social determinants of health of an entire community. However, Burton F. VanderLaan, MD, FACP, medical director of Priority Health, explained that precision medicine, specifically in precision oncology, seeks to do just the opposite by employing variation and individualizing treatment rather than standardizing it.

September 27th 2016

The Role of PBMs in Managing High-Cost Treatment Options

Stacey W. McCullough, DO, senior vice president of Pharmacy at Tennessee Oncology, PLLC; Bruce W. Sherman, MD, FCCP, FACOEM, medical director for Population Health Management for the RightOpt private exchange offering for Buck Consultants, A Xerox Company; and Glen D. Stettin, MD, senior vice president of clinical research and new solutions at Express Scripts, came together to discuss the role of pharmacy benefit managers (PBMs) as a means of helping to manage high-cost treatment options. The discussion, moderated by Bruce A. Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, was held during The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Care Meeting.

September 27th 2016

Evolution of the ACO Model to Meet the Needs of Oncology Patients and Payers

Julian Malinak, MPH, finance lead for the pioneer accountable care organization (ACO) and next generation ACO models and technical advisor for financial policy at CMS Innovation Center, explained that CMS, as well as other organizations, are pushing away from the traditional fee-for-service methods by creating delivery models like ACOs and employing various tools and services, such as bundled payments, and are beginning to examine these methods in the oncology setting.

September 27th 2016

Evaluation of Options and Outcomes in a "Me Too" Market

In the past 5 years, the FDA has approved 52 new agents for oncology use, and 24 of those agents have novel mechanisms, explained Stacey W. McCullough, PharmD, senior vice president of Pharmacy at Tennessee Oncology, PLLC, during her presentation at The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Care Meeting. With these emerging options in oncology care, there are 3 things to consider when choosing the appropriate option for the patient, she said.

September 26th 2016

A New Biomarker Predicts Response to Pembrolizumab in Advanced Melanoma

Surabhi Dangi-Garimella, PhD

A new study by researchers at the Perelman School of Medicine has identified a predictive biomarker in stage IV patients with melanoma being treated with the pembrolizumab.

September 23rd 2016

UnitedHealth's 2017 Formulary to Support Generic and Biosimilar Drugs

Surabhi Dangi-Garimella, PhD

UnitedHealth has posted a presentation on its website that provides an update to its pharmacy benefits and prescription drug lists for 2017.

September 22nd 2016

Cancer Prevention Possible Through Lifestyle Control, Says JAMA Oncology Study

Surabhi Dangi-Garimella, PhD

Research published in the journal JAMA Oncology argues that major lifestyle changes can significantly delay the onset of cancer.

September 22nd 2016

Carolina Breast Cancer Study Reinforces Relation Between Racial Disparity and QOL

Surabhi Dangi-Garimella, PhD

Research conducted at the University of North Carolina Lineberger Comprehensive Cancer Center has found that white women performed better than black women on physical and functional health-related quality-of-life (HRQOL) scores, but not spiritual HRQOL.

September 20th 2016

Colombia Takes a Stand on Price of Novartis' Leukemia Drug

Surabhi Dangi-Garimella, PhD

Colombia has decided to slash the price of imatinib mesylate (Gleevec), manufactured by Novartis, by nearly half.

September 20th 2016

Improved Design, Access, and Transparency of Trials Essential for Success of Cancer Moonshot

Surabhi Dangi-Garimella, PhD

The National Cancer Institute's Cancer Moonshot initiative received yet another boost following Vice President Joe Biden’s announcement of several activities to accelerate the pace of oncology clinical research.

September 19th 2016

Managing Neutropenia in Patients With Soft Tissue Sarcomas

AJMC Staff

Using prophylaxis with biosimilar granulocyte colony-stimulating factor can reduce the severity of neutropenia in patients with soft tissue sarcoma.

September 17th 2016

This Week in Managed Care: September 17, 2016

This week, the top managed care stories included news that Risa Lavizzo-Mourey, MD, MBA, will be leaving the Robert Wood Johnson Foundation, a report that obesity rate in the military are also on the rise, and CMS denied Ohio's proposal to charge fees for Medicaid.

September 16th 2016

ASCO President Dr Daniel F. Hayes Applauds Recommendations for Cancer Moonshot

Surabhi Dangi-Garimella, PhD

The American Journal of Managed Care reached out to Daniel F. Hayes, MD, FASCO, 2016-2017 president of the American Society of Clinical Oncology (ASCO), to understand his perception of how the recommendations of the Cancer Moonshot initiative's Blue Ribbon Panel would impact cancer care in the United States.

September 16th 2016

Obesity: A Growing Burden for Cancer Survivors

Priyam Vora

Patients with a history of cancer were more likely to suffer from obesity than the general population. This incidence was even greater in patients who were survivors of colorectal and breast cancers.

September 16th 2016

NCHS Report: Rising Survivorship in Pediatric Cancers, Brain Cancer Leading Cause of Death

Surabhi Dangi-Garimella, PhD

There has been a steady decline in death rates among children and adolescent patients diagnosed with cancer (ages 1 to 19 years), minus gender or racial disparity, between 1999 and 2014, according to a new report from the National Center for Health Statistics.

September 15th 2016

FDA Advisory Forces Company to Suspend US Sale of Screening Test

Surabhi Dangi-Garimella, PhD

Following an FDA advisory on ovarian cancer screening tests, London-based Abcodia has announced that it will temporarily stop sales of its Risk of Ovarian Cancer Algorithm test in the United States.

September 15th 2016

Oncotype DX May Not Be Economical for Decisions on Adjuvant Radiation

Surabhi Dangi-Garimella, PhD

A cost-effectiveness analysis has found that Oncotype DX may not be economical to make clinical decisions on adjuvant radiation treatment in patients with DCIS.

September 14th 2016

Intervention Improved Oncologist-Patient Communication, Not QOL or Hospice Use

Surabhi Dangi-Garimella, PhD

A study published in JAMA Oncology has found that interventions to improve patient-centered communication was successful in patients with advanced cancer, but it failed to improve quality of life (QOL), patient-physician relation, or healthcare utilization toward the end of life.

September 13th 2016

Daratumumab Lengthens PFS in Multiple Myeloma, but Increases Risk of Neutropenia

AJMC Staff

Although daratumumab reduced the risk of disease progression and death for patients with multiple myeloma, the drug was associated with a higher rate of neutropenia.

September 13th 2016

Growing Role of Genetic Counselors Could Improve Efficacy of Cancer Diagnosis and Treatment

Surabhi Dangi-Garimella, PhD

Insurance companies are making it mandatory for individuals to speak with qualified genetic counselors prior to testing for some hereditary cancers.

...

92 93 94 95 96 97 98 99 100

...

186 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions